Completed
EARLY PHASE1
INTERVENTIONAL
NCT01398280
Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine the effect of topical aminocaproic acid on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with rosacea. It is hypothesized that aminocaproic acid applied topically will alter the body's immune system in patients with rosacea by inhibiting activation of antimicrobial peptides.
Interventions
Name:
Topical aminocaproic acid (ACA) mixed with Vanicream
Type:
DRUG
Description:
25% Aminocaproic acid cream twice daily for up to 12 weeks.
Name:
Vehicle cream
Type:
DRUG
Description:
Vehicle cream moisturizer twice daily for up to 12 weeks
Primary Outcomes
Measure:
Kallikrein 5 (KLK5) Protease Activity
TimeFrame:
Up to 12 weeks
Description:
Serine protease activity of KLK5 in adult skin from patients with rosacea is measured after treatment with vehicle or aminocaproic acid cream. Protease activity of facial skin surface is monitored using a synthetic fluorogenic trypsin-like proteinase substrate. Protease activity is monitored as an increase of fluorescence (RFU/uL) with SpectraMax GEMINI EM.
Trial Information
NCT ID
NCT01398280
Status
Completed
Study Type
INTERVENTIONAL
Phases
EARLY PHASE1
Sponsor
University of California, San Diego
Last Updated
December 15, 2025